People
Less than one month after he was appointed as chief financial officer of Moderna, Jorge Gomez abruptly departed the company due to an ongoing investigation at his former company.
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
Today’s announcement from Seagen’s board of directors included difficult news regarding Clay Siegall, Ph.D. Until today, Siegall served as Seagen’s President, CEO and Chairman.
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
For Terry Coelho, being CFO is about becoming a trusted strategic partner across the business. It’s about building bridges.
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Athira investor Richard Kayne appears to be making a strong push for Dr. Ronald Krall, former chief medical officer of GlaxoSmithKline, to run the company, despite protests from Athira’s board.
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
David Sabatini has withdrawn his name for consideration for a faculty post at New York University Langone Health.
PRESS RELEASES